Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG7986) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Obinutuzumab Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inh Selective estrogen receptor degrader (SERD[2]) (GDC-0927/SRN-927, RG6047) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Hematology, Solid Tumor

Phase: PHASE I

Region:

Molecule:

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AU NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AU
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AZ NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AZ
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab CO NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab CO
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab DE NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab DE
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KR NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KR
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KY NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KY
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab MN NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab MN
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NC NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NC
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NZ NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NZ
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab PA NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab PA
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab RI NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab RI
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KR NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KR
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NZ NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NZ
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab AL NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab AL
NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab FL NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab FL
NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab FR NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab FR
NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab KY NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab KY
NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NC NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NC
NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NY NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), Obinutuzumab NY
NCT02631577—A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) ES NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) ES
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CO NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab CO
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab ES NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab ES
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GA NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GA
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TX NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TX
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FL NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FL
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) GA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) GA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NJ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NJ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) BE NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) BE
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CO NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CO
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CT NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CT
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab DK NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab DK
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab ES NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab ES
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab IT NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab IT
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab MA NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab MA
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NL NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NL
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NY NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NY
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab SC NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab SC
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab TN NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab TN
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) BE NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) BE
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) FR NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) FR
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) NY NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) NY
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) PA NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) PA
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) FR NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) FR
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) GB NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) GB
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
1 of 156 clinical trials
1-4 of 156 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK